Literature DB >> 9663711

Atypical heparin-induced thrombocytopenia complicated by intracardiac thrombus, effectively treated with ultra-low-dose rt-PA lysis and recombinant hirudin (Lepirudin).

K Olbrich1, M Wiersbitzky, W Wacke, P Eichler, H Zinke, M Schwock, B Möx, G Kraatz, W Motz, A Greinacher.   

Abstract

A serious retroperitoneal bleeding occurred in a 56-year-old male patient receiving unfractionated heparin due to multiple pulmonary embolism. After reducing the heparin dose, the patient developed a new pulmonary embolism and a large thrombus in the right atrium. Concomitantly, the platelet count dropped to a value of 29 g/l. Heparin-induced thrombocytopenia (HIT) was confirmed by a functional assay, the heparin-induced platelet activation (HIPA) assay, whereas the results of a platelet factor 4/heparin complex ELISA were repeatedly negative. This indicated that the patient's HIT antibodies were directed towards an antigen other than platelet factor 4/heparin complexes. For treatment of the atrial thrombus, an ultra-low-dose lysis with rt-PA (2 mg/h, intravenously) was administered for a period of 52 h, overlapping with systemic treatment with recombinant hirudin (Lepirudin, Refludan, 0.06-0.14 mg/kg/h intravenously). The aim was to enhance lysis of the thrombus without increasing the haematoma, and at the same time keep the risk of fulminant pulmonary embolism due to thrombus fragmentation as low as possible. The cardiac thrombus disappeared within 48 h, without new signs of pulmonary embolism. Platelet counts normalized within nine days.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9663711     DOI: 10.1097/00001721-199804000-00009

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  5 in total

Review 1.  Management of patients with heparin-induced thrombocytopenia: focus on recombinant hirudin.

Authors:  N Lubenow; A Greinacher
Journal:  J Thromb Thrombolysis       Date:  2000-11       Impact factor: 2.300

2.  Concurrent use of reteplase and lepirudin in the treatment of acute anterior wall myocardial infarction.

Authors:  I Chern; A Sharma; D Dennis
Journal:  J Thromb Thrombolysis       Date:  2001-10       Impact factor: 2.300

Review 3.  Non-vitamin K antagonist oral anticoagulants for the treatment of intracardiac thrombosis.

Authors:  Eiman Ghaffarpasand; Maneli D Tehrani; Jolanta Marszalek; Gerald Chi
Journal:  J Thromb Thrombolysis       Date:  2018-10       Impact factor: 2.300

4.  Heparin-induced thrombocytopenia associated with massive intracardiac thrombosis: a case report.

Authors:  Atheer Ahmed; Hamid Al-Mondhiry; Truman J Milling; David Campbell
Journal:  Case Rep Hematol       Date:  2012-03-29

5.  Safety and outcomes of thrombolytic therapy in patients with pulmonary embolism and thrombocytopenia: A systematic review.

Authors:  Fateen Ata; Wanis Hamad Ibrahim; Mohammad Nasser Affas; Haseeb Ahmad Khan; Hafiz Waqas Younas; Zakaria Maat; Sabah Elshayeb Ali Mohamed; Balqis Daoudi
Journal:  Qatar Med J       Date:  2022-08-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.